Cited 0 times in Scipus Cited Count

Long-term effectiveness and safety of tafluprost, travoprost, and latanoprost in korean patients with primary open-angle glaucoma or normal-tension glaucoma: A multicenter retrospective cohort study (lotus study)

DC Field Value Language
dc.contributor.authorKim, JM-
dc.contributor.authorSung, KR-
dc.contributor.authorKim, HK-
dc.contributor.authorPark, SW-
dc.contributor.authorLee, EJ-
dc.contributor.authorJeoung, JW-
dc.contributor.authorPark, HYL-
dc.contributor.authorAhn, J-
dc.contributor.authorYoo, C-
dc.contributor.authorKim, CY-
dc.date.accessioned2022-12-26T00:39:10Z-
dc.date.available2022-12-26T00:39:10Z-
dc.date.issued2021-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/23484-
dc.description.abstractThis multicenter retrospective cohort study compared the effectiveness and safety of long-term tafluprost, travoprost, or latanoprost in patients with primary open-angle glaucoma (POAG) or normal-tension glaucoma (NTG). Data were extracted from electronic medical records of 300 patients treated with tafluprost, travoprost, or latanoprost for >6 months. Propensity matching for age and sex was used for effectiveness and safety comparisons. The primary endpoint was visual field (VF) progression via mean deviation (MD) slope. Secondary endpoints were change of MD, intra-ocular pressure, pattern standard deviation, VF index, and advanced glaucoma intervention study score. Treatment-related adverse events (AEs) were also compared between groups. Overall, 216 POAG or NTG patients were matched into Match Set 1 (72 patients/group), and 177 NTG-only patients in Match Set 2 (59 patients/group) according to: age (mean: 61, 62 years) and sex (male: 53, 56%). There were no statistically significant between-group differences regarding MD slope (p = 0.413, p = 0.374 in Match Sets 1 and 2, respectively). There were no significant between-group dif-ferences/tendencies regarding secondary endpoints. No AEs were serious, and there were no significant between-group differences regarding reported AEs. In patients with POAG or NTG, long-term tafluprost, travoprost, or latanoprost showed similar effects. All three prostaglandin analogs had good long-term safety profiles.-
dc.language.isoen-
dc.titleLong-term effectiveness and safety of tafluprost, travoprost, and latanoprost in korean patients with primary open-angle glaucoma or normal-tension glaucoma: A multicenter retrospective cohort study (lotus study)-
dc.typeArticle-
dc.identifier.pmid34205421-
dc.identifier.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235659/-
dc.subject.keywordGlaucoma-
dc.subject.keywordLatanoprost-
dc.subject.keywordProstaglandin analogs-
dc.subject.keywordTafluprost-
dc.subject.keywordTravoprost-
dc.contributor.affiliatedAuthorAhn, J-
dc.type.localJournal Papers-
dc.identifier.doi10.3390/jcm10122717-
dc.citation.titleJournal of clinical medicine-
dc.citation.volume10-
dc.citation.number12-
dc.citation.date2021-
dc.citation.startPage2717-
dc.citation.endPage2717-
dc.identifier.bibliographicCitationJournal of clinical medicine, 10(12). : 2717-2717, 2021-
dc.identifier.eissn2077-0383-
dc.relation.journalidJ020770383-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Ophthalmology
Files in This Item:
34205421.pdfDownload

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse